Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard I Scher

Showing results (31-40 of 393) with videos related to

Pageof 40
Sort By:
Clinical Chemistry|January 4, 2019
Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical UtilityKlaus Pantel, Claudia Hille, Howard I Scher
JAMA Oncology|February 1, 2019
Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test-In ReplyPascal Bamford, Ryan Dittamore, Howard I Scher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
The association between measures of progression and survival in castrate-metastatic prostate cancerHoward I Scher, Mary Warren, Glenn Heller
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2007
Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testingAndrew J Vickers, Vennus Ballen, Howard I Scher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2011
Circulating tumor cells as biomarkers in prostate cancerDaniel C Danila, Martin Fleisher, Howard I Scher
The Lancet. Oncology|October 3, 2009
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetYu Chen, Nicola J Clegg, Howard I Scher
Current Opinion in Pharmacology|August 5, 2008
Targeting the androgen receptor pathway in prostate cancerYu Chen, Charles L Sawyers, Howard I Scher
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 1, 2007
Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy dataGlenn Heller, Michael W Kattan, Howard I Scher
Seminars in Oncology|October 23, 2003
Hsp90 as a therapeutic target in prostate cancerDavid B Solit, Howard I Scher, Neal Rosen
Clinical Chemistry|November 2, 2019
Toward Standardization of Preanalytical Procedures for Cell-Free DNA ProfilingDana W Y Tsui, Ethan Barnett, Howard I Scher
Pageof 40

Showing results (31-40 of 393) with videos related to

Sort By:
Pageof 40
Clinical Chemistry|January 4, 2019
Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical UtilityKlaus Pantel, Claudia Hille, Howard I Scher
JAMA Oncology|February 1, 2019
Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test-In ReplyPascal Bamford, Ryan Dittamore, Howard I Scher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
The association between measures of progression and survival in castrate-metastatic prostate cancerHoward I Scher, Mary Warren, Glenn Heller
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2007
Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testingAndrew J Vickers, Vennus Ballen, Howard I Scher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2011
Circulating tumor cells as biomarkers in prostate cancerDaniel C Danila, Martin Fleisher, Howard I Scher
The Lancet. Oncology|October 3, 2009
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetYu Chen, Nicola J Clegg, Howard I Scher
Current Opinion in Pharmacology|August 5, 2008
Targeting the androgen receptor pathway in prostate cancerYu Chen, Charles L Sawyers, Howard I Scher
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 1, 2007
Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy dataGlenn Heller, Michael W Kattan, Howard I Scher
Seminars in Oncology|October 23, 2003
Hsp90 as a therapeutic target in prostate cancerDavid B Solit, Howard I Scher, Neal Rosen
Clinical Chemistry|November 2, 2019
Toward Standardization of Preanalytical Procedures for Cell-Free DNA ProfilingDana W Y Tsui, Ethan Barnett, Howard I Scher
Pageof 40